PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib

BackgroundLenvatinib, regorafenib and anti-programmed cell death protein-1 (PD-1) immunotherapy have shown promising clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure, respectively. However, the combination of the two treatments has not been reported....

Full description

Bibliographic Details
Main Authors: Yongkang Xu, Shumin Fu, Kai Shang, Jiayu Zeng, Ye Mao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
PD-1 inhibitors
lenvatinib
regorafenib
sorafenib
hepatocellular carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.958869/full

Similar Items

Similar Items